Contraception
Return to fertility after cessation of a continuous oral contraceptive

https://doi.org/10.1016/j.fertnstert.2008.02.122Get rights and content
Under an Elsevier user license
open archive

Objective

To evaluate the return to fertility among women planning to become pregnant after the use of a continuous regimen of levonorgestrel 90 μg and ethinyl E2 20 μg.

Design

Descriptive analysis of pregnancy outcomes after participation in a contraceptive trial.

Setting

Multicenter trial.

Subject(s)

Participants in a phase 3 contraceptive trial who discontinued to become pregnant.

Intervention(s)

Eligible subjects were contacted at 3 and 12 months after treatment discontinuation to determine if and when they had conceived.

Main Outcome Measure(s)

Kaplan-Meier analysis displaying the time until conception after oral contraceptive discontinuation.

Result(s)

In the phase 3 trial, 34 of 2,134 subjects cited a desire for pregnancy as a reason for discontinuation. Of these, 4 were already pregnant before stopping treatment, 4 initiated other contraception, and 5 were lost to follow-up. Of the remaining 21 subjects at risk of pregnancy, the pregnancy rate was 57% at 3 months, 81% at 12 months, and 86% (18 of 21) (95% confidence interval 64% to 97%) at 13 months after discontinuation of treatment.

Conclusion(s)

These findings suggest that a continuous oral contraceptive with levonorgestrel 90 μg and ethinyl E2 20 μg does not delay the return to fertility.

Key Words

Return to fertility
oral contraceptive
low-dose
continuous
noncyclic

Cited by (0)

Supported by a grant from Wyeth Research, Collegeville, Pa.

K.B. was an investigator for this poststudy follow-up and received research funding from Wyeth Research, Collegeville, Pa. Other sources of research funding and/or financial relationships include Novo Nordisk (consultant), Organon (speaker and investigator), Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfizer, and MGI Pharma (investigator). S.M., G.G., and G.C. are employees of Wyeth Research. Other financial affiliation for G.G. is Johnson & Johnson. S.M. and G.C. have no other financial affiliation to disclose.